Soluble Expression of Antimicrobial Peptide BSN-37 from Escherichia coli by SUMO Fusion Technology
The Protein Journal · 2023
DOI: 10.1007/s10930-023-10144-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Protein Journal, 2023. Verfasst von Yanzhao Xu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Postdoctoral Research Station, College of Veterinary Medicine, Henan Agricultural University, Zhengzhou, 450002, China. xuyanzhao@hist.edu.cn. Hauptthemen laut MEDLINE: Escherichia coli, Antimicrobial Peptides. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Antimicrobial peptides (AMPs) are a kind of small molecular peptide that an organism produces to resist the invasion of foreign microorganisms. AMP BSN-37 is a bovine AMP that exhibits high antibacterial activity. In this paper, the optimized gene AMP BSN-37 was cloned into pCold-SUMO for fusion expression by recombinant DNA technology. The gene sequence of AMP BSN-37 was obtained by codons reverse translation, and the codons were optimized according to the codons preference of Escherichia coli (E. coli). The recombinant plasmid was constructed and identified by PCR, enzyme digestion and sequencing. Then the recombinant plasmid was transformed into BL21 E. coli to induce expression, and the IPTG concentration and time were optimized. The expressed soluble fusion protein SUMO-BSN-37 was purified by chromatography and then cleaved by SUMO proteases to release BSN-37. SDS-PAGE electrophoresis and Western blotting were used for identification. The recombinant plasmid pCold-SUMO-BSN-37 was obtained, and the fusion AMP BSN-37 was preliminarily expressed in BL21. After optimization, the optimal expression condition was 37 ℃ with 0.4 µM IPTG and 6 h incubation. Under optimal conditions, a large amount of fusion AMP BSN-37 was obtained by purification. Western blotting showed that the fusion peptide was successfully expressed and had good activity. The expressed BSN-37 showed antimicrobial activity similar to that of synthesized BSN-37. In this study, soluble expression products of AMP BSN-37 were obtained, and the problem regarding the limited source of AMP BSN-37 could be effectively solved, laying a foundation for further research on AMP BSN-37.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Postdoctoral Research Station, College of Veterinary Medicine, Henan Agricultural University, Zhengzhou, 450002, China. xuyanzhao@hist.edu.cn.
- Postdoctoral Research Base, Henan Institute of Science and Technology, Xinxiang, 453003, China. xuyanzhao@hist.edu.cn.
- College of Animal Science and Veterinary Medicine, Henan Institute of Science and Technology, Xinxiang, 453003, China. xuyanzhao@hist.edu.cn.
- College of Animal Science and Veterinary Medicine, Henan Institute of Science and Technology, Xinxiang, 453003, China.
- Postdoctoral Research Base, Henan Institute of Science and Technology, Xinxiang, 453003, China.
- Postdoctoral Research Station, College of Veterinary Medicine, Henan Agricultural University, Zhengzhou, 450002, China. zhanggaiping2003@126.com.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Xu, Y., Dong, M., Wang, Q., Sun, Y., Hang, B., Zhang, H., Hu, J., & Zhang, G. (2023). Soluble Expression of Antimicrobial Peptide BSN-37 from Escherichia coli by SUMO Fusion Technology. The Protein Journal. https://doi.org/10.1007/s10930-023-10144-2
Vancouver
Xu Y, Dong M, Wang Q, Sun Y, Hang B, Zhang H, et al. Soluble Expression of Antimicrobial Peptide BSN-37 from Escherichia coli by SUMO Fusion Technology. The Protein Journal. 2023. doi:10.1007/s10930-023-10144-2
BibTeX
@article{Xu2023,
author = {Xu, Yanzhao and Dong, Mengmeng and Wang, Qing and Sun, Yawei and Hang, Bolin and Zhang, Huihui and Hu, Jianhe and Zhang, Gaiping},
title = {Soluble Expression of Antimicrobial Peptide BSN-37 from Escherichia coli by SUMO Fusion Technology},
journal = {The Protein Journal},
year = {2023},
doi = {10.1007/s10930-023-10144-2}
}
EUVIMED